I. Belinchón Romero

发表

Evidence-based guidelines of the spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites (nails, scalp, palms, and soles).

R. Ruiz‐Villaverde, R. F. Lafuente-Urrez, M. Sánchez-Regaña, 2014, Actas dermo-sifiliograficas.

Management of Moderate to Severe Psoriasis in Routine Clinical Practice in Spanish Hospitals

P. de la Cueva-Dobao, J. López-Estebaranz, I. Belinchón Romero, 2018, Actas Dermo-Sifiliográficas (English Edition).

Management of Moderate to Severe Psoriasis in Routine Clinical Practice in Spanish Hospitals.

P. de la Cueva-Dobao, J. López-Estebaranz, I. Belinchón Romero, 2018, Actas dermo-sifiliograficas.

PASI 100 response rates in moderate to severe psoriasis: a systematic literature review and analysis of clinical practice guidelines

E. Dauden, Á. González-Cantero, I. Belinchón Romero, 2021, The Journal of dermatological treatment.

Homeostasis model assessment (HOMA) and insulin resistance in psoriasis

J. M. Ramos Rincón, I. Belinchón Romero, D. Romero-Pérez, 2021, Actas Dermo-Sifiliográficas (English Edition).

Coding of Dermatologic Diagnoses: An Unresolved Issue.

I. Belinchón Romero, 2018, Actas dermo-sifiliograficas.

Ixekizumab and Psoriasis in the Real World.

I. Belinchón Romero, 2019, Actas dermo-sifiliograficas.

[Utilization of dermatology services among the immigrant population].

J. M. Ramos Rincón, I. Belinchón Romero, I. Betlloch Mas, 2008, Gaceta sanitaria.

Criteria used to define tumor necrosis factor-alpha inhibitors failure in patients with moderate-to-severe psoriasis: a systematic literature review

J. Carrascosa, I. Belinchón Romero, P. de la Cueva Dobao, 2023, Annals of medicine.

Long‐term secukinumab efficacy and safety in bio‐naïve patients with moderate‐to‐severe cutaneous psoriasis: A real‐world retrospective noninterventional multicentric experience (128 patients)

I. Belinchón Romero, J. S. Sánchez Carazo, A. Mateu Puchades, 2023, JEADV Clinical Practice.

[Adverse reactions during biological therapy for psoriasis: results of a survey of the Spanish Psoriasis Group].

D. Vidal, J. Carrascosa, M. Alsina, 2010, Actas dermo-sifiliograficas.

A prospective multi-center study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients.

I. Belinchón Romero, J. S. Sánchez Carazo, J. O. Ortiz Salvador, 2019, Journal of the American Academy of Dermatology.

Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Between 2008 and 2016.

I. García-Doval, C. Ferrándiz, P. de la Cueva-Dobao, 2018, Actas dermo-sifiliograficas.

Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document

Á. González-Cantero, I. Belinchón Romero, J. C. Carrascosa Carrillo, 2021, Annals medicus.

Practical update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPS) on the Treatment of Psoriasis with Biologic Therapy. Part 1. Concepts and General Management of Psoriasis with Biologic Therapy.

L. Puig, L. Salgado-Boquete, I. Belinchón Romero, 2021, Actas dermo-sifiliograficas.

Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts

E. Pérez-Pampín, F. Vanaclocha, I. García-Doval, 2017, The British journal of dermatology.